AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
An estimated 2.2 million people worldwide are diagnosed with lung cancer each year. AstraZeneca (AZ) has shared positive results from a late-stage study evaluating Tagrisso (osimertinib) as an additional treatment for certain lung cancer patients.
The phase 3 ADAURA trial enrolled 682 patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who had undergone surgery to remove their primary tumour.
Patients were treated with Tagrisso 80mg once-daily oral tablets or placebo for three years or until disease recurrence.
The results, which were presented at the American Society of Clinical Oncology annual meeting, showed that the drug reduced the risk of death by 51% compared to placebo in both the primary analysis population (patients with stages 2 to 3a EGFRm NSCLC) and in the overall trial population (stages 1b to 3a).
In the primary analysis population, an estimated 85% of Tagrisso-treated patients were alive at five years compared to 73% in the placebo cohort. In the overall trial population, around 88% of patients treated with Tagrisso were alive at five years compared to 78% on placebo.
